|
Treatments
|
Dose (mg/kg)
| |
Behavioural seizure
| |
|---|
|
kindling development (day)
|
Number
|
Duration (s)
|
Seizure mean stage
|
|---|
|
Myoclonic jerks
|
Myoclonic jerks latency
|
Onset of clonic seizures
|
Latency to generalized clonic-tonic seizures
|
Duration of generalized clonic-tonic seizures
|
|---|
|
Vehicle + Saline
|
– + –
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
|
Vehicle + PTZ
|
– + 30
|
30.00 ± 1.65
|
64.32 ± 2.45
|
45.45 ± 8.55
|
61.83 ± 8.61
|
185.45 ± 15.55
|
19.48 ± 1.32
|
4.00 ± 0.00
|
|
IGEFA + PTZ
|
15 + 30
|
32.21 ± 2.45
|
28.23 ± 2.14**
|
68.54 ± 5.25
|
75.16 ± 7.61
|
252.27 ± 24.14*
|
14.12 ± 1.25
|
2.33 ± 0.45*
|
|
IGEFA + PTZ
|
30 + 30
|
44.13 ± 2.28*
|
18.48 ± 2.13**
|
85.48 ± 4.47
|
185.21 ± 9.15***
|
324.15 ± 27.12***
|
8.24 ± 0.16**
|
2.16 ± 0.27*
|
|
IGEFA + PTZ
|
60 + 30
|
44.36 ± 2.32*
|
14.25 ± 2.34**
|
126.53 ± 8.15***
|
285.20 ± 7.62***
|
388.22 ± 35.26***
|
4.86 ± 0.24***
|
1.83 ± 0.28**
|
|
IGEFA + PTZ
|
90 + 30
|
43.72 ± 2.48*
|
8.45 ± 1.22***
|
173.62 ± 9.34***
|
371.52 ± 6.27***
|
495.48 ± 57.41***
|
3.29 ± 0.23***
|
1.33 ± 0.44**
|
|
SVA + PTZ
|
300 + 30
|
43.58 ± 2.34**
|
7.24 ± 1.56***
|
157.47 ± 8.52***
|
245.57 ± 6.45***
|
582.54 ± 48.36***
|
2.27 ± 0.15***
|
1.16 ± 0.27**
|
|
SVA + Saline
|
300 + –
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
|
IGEFA + Saline
|
90 + –
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
- Results are expressed as mean ± S.E.M., for 6 animals. Data were analysis by two-way ANOVA, followed by Newman-Keuls post hoc test
-
PTZ pentylenetetrazol, SVA sodium valproate, IGEFA iridoid glycosides extracts of Feretia apodenthera
- *P < 0.05, **P < 0.01, ***P < 0.001, significantly different compared to the vehicle-treated pentylentetrazole mice
